Ascendis Pharma A/S

NASDAQ:ASND

Biotechnology

Healthcare
$270.33 -0.02%

-$0.05 today

Market cap
$17.73B
Beta
0.39
P/E (TTM)
24.5
EPS (TTM)
$8.21
52W Low $160.86High $250.74

Volume 0.57M

Average 0.64M

ASND EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Ascendis Pharma A/SNASDAQ: ASND

EBITDA · Q3 FY2026 · quarter ended Sep 2026

EBITDA turns positive

Q3 FY2026 EBITDA was €128.45M, compared with -€53.35M a year earlier. Trailing-twelve-month EBITDA was €259.93M.

Context

  • EBITDA amounted to 15.9% of revenue in FY2025, down 63.9 pp from a year earlier.
  • EBITDA grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 13 analysts of €1.31B (+1293.4%) for the fiscal year ending Dec 2026, a step up from the +62.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
€128.45M+88.7% QoQ
Last fiscal yearDec 2025
-€109.8M+62.1% YoY
LTMSep 2026
€259.93M+295.2% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+340.8%-919.7%-1260.4 pp
1 year+62.1%+1293.4%+1231.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

EUR · from the income statement

Latest · FY2025
(109.8M) EUR
Year-over-year change
+62.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ASND compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +295.2% is the 2nd highest of 11, against a peer median of -7.1%.
  • EBITDA amounts to 21.5% of revenue for ASND, versus a peer median of 53.1%.
ASND Competitors
EBITDA for ASND and competitors
Company Period LTM YoY 3-year CAGR% of revenue
UTHRUnited Therapeutics CorporationLTM Jun 2026$1.68B USD-2.3%+20.5%53.1%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$949.9M USD+39.8%+41.2%25.7%
ASNDAscendis Pharma A/SLTM Sep 2026€259.93M EUR+295.2%—21.5%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$46.13M USD+1163.1%—14.7%
CORTCorcept Therapeutics IncorporatedLTM Jun 2026$28.79M USD-77.5%-17.0%3.5%
SEPNSepterna, Inc.LTM Sep 2026-$57.07M USD+24.4%—59.3%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026-$148.59M USD-85.2%——
STOKStoke Therapeutics, Inc.LTM Mar 2026-$164.11M USD-405.9%—511.5%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-$503.35M USD-11.9%—75.2%
INSMInsmed IncorporatedLTM Jun 2026-$770.76M USD+17.8%—67.8%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-$81.69B USD-10676.6%+29.2%8.0%
Peer median (excluding ASND) —-7.1%+24.9%53.1%

Competitors are the stored peer set for ASND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.78M51.17M266.72M363.64M691.71M
Cost of Revenue3.52M12.14M44.4M44.26M103.18M
Gross Profit4.26M39.04M222.32M319.38M588.53M
Gross Margin54.7%76.3%83.4%87.8%85.1%
Research & Development295.87M379.62M413.45M307M283.5M
Selling, General & Admin160.18M215.85M258.79M284.55M435.92M
Operating Expenses456.05M600.85M677.86M598.15M719.42M
Depreciation & Amortization15.39M17.96M18.91M17.71M17M
EBITDA(364.64M)(529.18M)(411.17M)(290.02M)(109.8M)
EBITDA Margin-4688.1%-1034.1%-154.2%-79.8%-15.9%
Operating Income(451.79M)(561.81M)(455.54M)(278.76M)(130.89M)
Operating Margin-5808.6%-1097.9%-170.8%-76.7%-18.9%
Interest Income692K7.43M16.86M14.36M14.7M
Interest Expense3.91M30.68M44.07M65.5M77.46M
Other Income / Expenses67.85M(16M)(18.6M)(94.48M)(73.37M)
Income Before Tax(383.94M)(577.82M)(474.14M)(373.24M)(204.26M)
Pre-Tax Margin-4936.3%-1129.1%-177.8%-102.6%-29.5%
Income Tax Expense(367K)5.38M7.3M4.84M14.78M
Net Income(383.58M)(583.19M)(481.45M)(378.08M)(219.03M)
Net Margin-4931.6%-1139.6%-180.5%-104.0%-31.7%
EPS (Basic)(7.00)(10.40)(8.55)(6.53)(3.62)
EPS (Diluted)(7.00)(10.40)(8.55)(6.53)(3.62)
Weighted Avg Shares54.77M56.07M56.29M57.89M60.61M
Weighted Avg Shares (Diluted)54.77M56.07M56.29M57.89M60.61M

Ascendis Pharma A/S

NASDAQ:ASND

Intrinsic Alpha fair value

Locked

Current Price

$270.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.